Principles and Practice of Pharmacology for Anaesthetists

Principles and Practice of Pharmacology for Anaesthetists

Volumn , Issue , 2008, Pages 1-366

  Calvey, T N ^a   Williams, N E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889386422     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781405194853     Document Type: Book

References (387)

1. Bates, I.P. (1985) Permeability of the blood-brain barrier. Trends in Pharmacological Sciences 6, 447-450.
2. Birkett, D.J., Mackenzie, P.I., Veronese, M.E. & Miners, J.O. (1993) In vitro approaches can predict human drug metabolism. Trends in Pharmacological Sciences 14, 292-294.
3. Calvey, T.N. (2001) Enzymes. Anaesthesia and Intensive Care Medicine 2, 322-323.
4. Calvey, T.N. (2005) Enzyme inducers and inhibitors: addition, subtraction and synergism. Anaesthesia and Intensive Care Medicine 6, 139-140.
5. Chang, G.W.M. & Kam, P.C.A. (1999) The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 54, 42-50.
6. Cholerton, S., Daly, A.K.&Idle, J.R. (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacological Sciences 13, 434-439.
7. Fehrenbach, A. (1987) Drugs in breast milk. British Journal of Pharmaceutical Practice 9, 288-290.
8. George, C.F. (1981) Drug metabolism by the gastro-intestinal mucosa. Clinical Pharmacokinetics 6, 259-274.
9. Gonzalez, F.J. (1992) Human cytochromes P450: problems and prospects. Trends in Pharmacological Sciences 13, 346-352.
10. Guengerich, F.P. (1989) Characterization of human microsomal cytochrome P-450 enzymes. Annual Review of Pharmacology and Toxicology 29, 241-264.
11. Iohom, G., Fitzgerald,D.&Cunningham, A.J. (2004) Principles of pharmacogenetics-implications for the anaesthetist. British Journal of Anaesthesia 93, 440-450.
12. Kharasch, E.D. & Thummel, K.E. (1993) Identification of cytochrome P450 2E1 as the predominant enzyme catalysing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 79, 795-807.
13. Krishna, D.R. & Klotz, U. (1994) Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics 26, 144-160.
14. Lieber, C.S. (1997) Cytochrome P-450 2E1: its physiological and pathological role. Physiological Reviews 77, 517-544.
15. Lin, J.H & Lu, A.Y. (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annual Review of Pharmacology and Toxicology 41, 535-567.
16. Okey, A.B. (1990) Enzyme induction in the cytochrome P-450 system. Pharmacology and Therapeutics 45, 241-298.
17. Pardridge,W.M. (1988) Recent advances in blood-brain barrier transport. Annual Review of Pharmacology and Toxicology 28, 25-39.
18. Pleuvry, B.J. (2002) Body compartments and drug distribution. Anaesthesia and Intensive Care Medicine 3, 256-260.
19. Pleuvry, B.J. (2005) Factors affecting drug absorption and distribution. Anaesthesia and Intensive Care Medicine 6, 135-138.
20. Routledge, P.A. (1986) The plasma protein binding of basic drugs. British Journal of Clinical Pharmacology 22, 499-506.
21. Schinkel, A.H. (1997) The physiological function of drugtransporting P-glycoproteins. Seminars in Cancer Biology 3, 161-170.
22. Somogyi, A. (1996) Renal transport of drugs: specificity and molecular mechanisms. Clinical and Experimental Pharmacology and Physiology 23, 986-989.
23. Spatzeneger,M.&Jaeger,W. (1995) Clinical importance ofhepatic cytochromeP450in drugmetabolism. DrugMetabolism Reviews 27, 397-417.
24. Stoughton, R.B. (1989) Percutaneous absorption of drugs. Annual Review of Pharmacology and Toxicology 29, 55-69.
25. Tamai, I. & Tsuji, A. (2000) Transporter-mediated permeation of drugs across the blood-brain barrier. Journal of Pharmaceutical Sciences 89, 1371-1388.
26. Tanaka, E. (1999) Update: genetic polymorphism of drug metabolizing enzymes in humans. Journal of Clinical Pharmacy and Therapeutics 24, 323-329.
27. Tucker, G.T. (1979) Drug metabolism. British Journal of Anaesthesia 51, 603-618.
28. Tucker, G.T. (1994) Clinical implications of genetic polymorphism in drug metabolism. Journal of Pharmacy and Pharmacology 46, 417-424.
29. Wood, M. (1997) Drug distribution: less passive, more active? Anesthesiology 87, 1274-1276.
30. Zhang, Y. & Benet, L.Z. (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and Pglycoprotein. Clinical Pharmacokinetics 40, 159-168.
31. Benet, L.Z. & Galeazzi, R.L. (1979) Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences 68, 1071-1074.
32. Coetzee, J.F. (2005) Principles of intravenous drug infusion. Anaesthesia and Intensive Care Medicine 6, 141-144.
33. Gibaldi, M. & Perrier, D. (1982) Pharmacokinetics, 2nd edn. New York: Marcel Dekker.
34. Glen, I. (2002) Pharmacokinetic analysis. Anaesthesia and Intensive Care Medicine 3, 263-265.
35. Gupta, V.L.&Glass, P.S.A. (1998) Total intravenous anesthesia. In: Longnecker, D.E., Tinker, J.H. & Morgan, G.E. (eds.), Principles and Practice of Anesthesiology. St. Louis: Mosby, pp. 1260-1293.
36. Lin, J.H. & Lu, A.Y. (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annual Review of Pharmacology and Toxicology 41, 535-567.
37. Marsh,B.,White, M.,Morton,N.&Kenny, G.N.C. (1991) Pharmacokineticmodel driven infusion of propofol in children. British Journal of Anaesthesia 67, 41-48.
38. Pleuvry, B. (2002) Pharmacodynamics: concentration-response relationships and hysteresis. Anaesthesia and Intensive Care Medicine 3, 269-271.
39. Price, H.L., Kovnat, P.J., Safer, J.N., Conner, E.H. & Price, M.L. (1960) The uptake of thiopental by body tissues and its relation to the duration of narcosis. Clinical Pharmacology and Therapeutics 1, 16-22.
40. Prys-Roberts, C. & Hug, C.C. (eds) (1984) Pharmacokinetics of Anaesthesia. Oxford: Blackwell Scientific Publications.
41. Riegelman, S., Loo, J.C.K. & Rowland, M. (1968) Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. Journal of Pharmaceutical Sciences 57, 117-123.
42. Rowland, M. & Tozer, T.N. (1995) Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Baltimore: Williams & Wilkins.
43. Schnider, T.W., Gaeta, R., Brose, W., Minto, C.F., Gregg, K.M. & Schafer, S.L. (1996) Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. Anesthesiology 84, 1043-1050.
44. Schuttler, J.,Kloos, S., Schwilden,H.&Stoeckel, H. (1988)TIVA with propofol and alfentanil by computer assisted infusions. Anaesthesia 43(Suppl), 2-7.
45. Shafer, S.L.&Varvel, J.R. (1991) Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 74, 53-63.
46. Stanski,D.R.&Watkins,W.D. (1982)DrugDisposition in Anesthesia. New York: Grune & Stratton.
47. Tozer, T.N. (1981) Concepts basic to pharmacokinetics. Pharmacology and Therapeutics 12, 109-131.
48. Wilkinson, G.R. (1987) Clearance approaches in pharmacology. Pharmacological Reviews 39, 1-47.
49. Wright,P.M.C. (1998) Population based pharmacokinetic analysis: why do we need it; what is it; and what has it told us about anaesthetics? British Journal of Anaesthesia 80, 488-501.
50. Berridge, M. (1997) Elementary and global aspects of calcium signalling. Journal of Physiology 499, 291-306.
51. Carafoli, E. (2002) Calcium signaling: a tale for all seasons. Proceedings of the National Academy of Sciences USA 99, 1115-1122.
52. Changeux, J.-P., Giraudat, J.&Dennis, M. (1987) The nicotinic acetylcholine receptor; molecular architecture of a ligandregulated ion channel. Trends in Pharmacological Sciences 8, 459-465.
53. De Ligt, R.A.F., Kourounakis, A.P. & Ijzerman, A.P. (2000) Inverse agonism at G protein-coupled receptors: pathophysiological significance and implications for drug discovery. British Journal of Pharmacology 130, 1-12.
54. Fergusson, S.S.G. (2001) Evolving concepts in G proteincoupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacological Reviews 53, 1-24.
55. Gilman, A.G. (1987) G proteins: transducers of receptorgenerated signals. Annual Review of Biochemistry 56, 615-649.
56. Kenakin, T. (1997) Pharmacologic Analysis of Drug-Receptor Interactions, 3rd edn. New York: Lipincott-Raven.
57. Monod, J.,Wyman, J.&Changeux, J.-P. (1965) Onthe nature of allosteric transitions: a plausible model. Journal ofMolecular Biology 12, 88-118.
58. Palmer, R.M.J., Ferrige, A.G.&Moncada, S. (1987) Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526.
59. Pleuvry, B.J. (2004) Receptors, agonists and antagonists. Anaesthesia and Intensive Care Medicine 5, 350-352.
60. Prince, R.J. (2004) Ion channels. Anaesthesia and Intensive Care Medicine 5, 348-349.
61. Quinn, A.C., Petros, A.J. & Vallance, P. (1995) Nitric oxide: an endogenous gas. British Journal of Anaesthesia 74, 443-451.
62. Rang, H.P., Dale, M.M., Ritter, J.M.&Moore, P.K. (2003) Pharmacology, 5th edn. Edinburgh: Churchill-Livingstone.
63. Schwinn, D.A. (1993) Adrenoceptors as models for G proteincoupled receptors: structure, function and regulation. British Journal of Anaesthesia 71, 77-85.
64. Stephenson, R.P. (1956) A modification of receptor theory. British Journal of Pharmacology 11, 379-393.
65. Sutherland, E.W.&Rall,T.W. (1960) The relation of adenosine-3',5'-phosphate and phosphorylase to the actions of catecholamines and other hormones. Pharmacological Reviews 12, 265-299.
66. Zaugg, M. & Schaub M.C. (2004) Cellular mechanisms in sympatho-modulation of the heart. British Journal of Anaesthesia 93, 34-52.
67. Gillman, P.K. (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia 95, 434-441.
68. Halsey, M.J. (1987) Drug interactions in anaesthesia. British Journal of Anaesthesia 59, 112-123.
69. Johnston, R.R., Eger, E.I., II&Wilson, C. (1976) A comparative interaction of epinephrine with enflurane, isoflurane and halothane in man. Anesthesia and Analgesia 55, 709-712.
70. Karalliedde, L. & Henry, J. (1998) Handbook of Drug Interactions. London: Arnold.
71. Oikkola, K.T.,Aranko, K., Saarnivaara, L., et al. (1993)Apotentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics 53, 298-305.
72. Pleuvry, B.J. (2005) Pharmacodynamic and pharmacokinetic drug interactions. Anaesthesia and Intensive Care Medicine 6, 129-133.
73. Riley, B.B. (1970) Incompatibilities in intravenous solutions. Journal of Hospital Pharmacy 28, 228-240.
74. Rolan, P.E. (1994) Plasma protein displacement interactions-why are they still regarded as clinically significant? British Journal of Clinical Pharmacology 37, 125-128.
75. Soni, N. (1987) Mechanisms of drug interactions (Appendix III). In: Feldman, S., Scurr, C.F. & Paton, W. (eds.), Drugs in Anaesthesia: Mechanisms of Action. London: Edward Arnold, pp. 408-427.
76. Stockley, I.H. (2000) Drug Interactions, 5th edn. London: The Pharmaceutical Press.
77. Thummel, K.E. & Wilkinson, G.R. (1998) In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 38, 389-430.
78. Wood,M. (1991) Pharmacokinetic drug interactions in anaesthetic practice. Clinical Pharmacokinetics 21, 285-307.
79. Altman, D.G. (1991) Practical Statistics for Medical Research. London: Chapman & Hall.
80. Armitage, P. & Berry, G. (1987) Statistical Methods in Medical Research, 2nd edn. Oxford: Blackwell Scientific Publications.
81. Bulpitt, C.J. (1987) Confidence intervals. Lancet 1, 494-497.
82. Christiensen, J.H. & Andreasen, F. (1978) Individual variation in the response to thiopental. Acta Anaesthetica Scandinavica 22, 303-313.
83. Churchill-Davidson, H.C. &Wise, R.P. (1963) Neuromuscular transmission in the newborn infant. Anesthesiology 24, 271-278.
84. Crooks, J., O'Malley, K. & Stevenson, I.H. (1976) Pharmacokinetics in the elderly. Clinical Pharmacokinetics 1, 280-296.
85. Dundee, J.W. & Gray, T.C. (1953) Resistance to d-tubocurarine chloride in the presence of liver damage. Lancet 11, 16-17.
86. Duvaldestin, P., Agoston, S., Henzel, D., et al. (1978) Pancuronium pharmacokinetics in patientswith liver cirrhosis. British Journal of Anaesthesia 50, 1131-1136.
87. Friis-Hansen, B. (1961) Body water compartments in children. Changes during growth and related changes in body composition. Pediatrics 28, 169-181.
88. Gardner, M.J.&Altman,D.G. (1989) Statistics with Confidence. London: British Medical Journal.
89. Greenblatt, D.J., Sellers, E.M. & Shader, R.I. (1982) Drug therapy: drug disposition in old age. New England Journal of Medicine 306, 1081.
90. Keslin, I. (2002) Statistic. Anaesthesia and Intensive Care Medicine 3, 428-433; and 4, 203-205.
91. Kirkwood, B.R. (1980) Essentials of Medical Statistics. Oxford: Blackwell Scientific Publications.
92. Muravchick, S. (1986) Immediate and long-term nervous systemeffects of anaesthesia in elderly patients. Clinics inAnesthesiology 4, 1035-1048.
93. Perucca, E.&Crema, A. (1982) Plasma protein binding of drugs in pregnancy. Clinical Pharmacokinetics 7, 336-352.
94. Rylance, G. (1981) Drugs in children. British Medical Journal 282, 50-51.
95. Smith, C.L. & Bush, G.H. (1985) Anaesthesia and progressive muscular dystrophy. British Journal ofAnaesthesia 57, 1113-1118.
96. Vestal, R.E. (1978) Drug use in the elderly: a review of problems and special considerations. Drugs 16, 358-362.
97. Wilkinson, G.R.&Shenker, S. (1975) Drug disposition and liver disease. Drug Metabolism Reviews 4, 139-175.
98. Axon, A.D. & Hunter, J.M. (2004) Anaphylaxis and anaesthesia-all clear now? British Journal of Anaesthesia 93, 501-503.
99. Dean, G. (1971) The Porphyrias: A Story of Inheritance and Environment, 2nd edn. London: Pitman, pp. 1-118.
100. Ellis, F.R.&Halsall, P.J. (2002)Malignant hyperthermia.Anaesthesia and Intensive Care Medicine 3, 222-225.
101. Ewan, P.W. (1998) Anaphylaxis. British Medical Journal 316, 1442-1445.
102. Fisher, M. (1995) Treatment of acute anaphylaxis. BritishMedical Journal 311, 731-733.
103. Iohom, G., Fitzgerald,D.&Cunningham, A.J. (2004) Principles of pharmacogenetics-implications for the anaesthetist. British Journal of Anaesthesia 93, 440-450.
104. James, M.F.M. & Hift, R.M. (2000) Porphyrias. British Journal of Anaesthesia 85, 143-153.
105. Jensen, F.S., Schwartz, M. & Viby-Mogensen, J. (1995) Identification of human plasma cholinesterase variants using molecular biological techniques. Acta Anaesthesiologica Scandinavica 39, 142-149.
106. Kalow,W. (1993) Pharmacogenetics: its biological roots and the medical challenge. Clinical Pharmacology and Therapeutics 54, 235-241.
107. Kroigaard, M., Garvey, L.H., Menne, T. & Husum, B. (2005) Allergic reactions in anaesthesia: are suspected causes confirmed on subsequent testing? British Journal of Anaesthesia 95, 468-471.
108. La Du, B.N. (1995) Butyrylcholinesterase variants and the new methods of molecular biology. Acta Anaesthesiologica Scandinavica 39, 139-141.
109. Laroche, D., Vergnaud, M.C., Sillard, B., et al. (1991) Biochemical markers of anaphylactoid reactions to drugs: comparison of plasma histamine and tryptase. Anesthesiology 75, 945-949.
110. McIndoe, A. (2001) Recognition and management of anaphylactic and anaphylactoid reactions. Anaesthesia and Intensive Care Medicine 2, 402-403.
111. Mertes, P. M. & Laxenaire, M.-C. (2002) Allergic reactions occurring during anaesthesia. European Journal of Anaesthesiology 19, 240-262.
112. Mertes, P.M., Laxenaire, M.-C. & Alla, F. (2003) Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 99, 536-545.
113. Neugut, A.I., Ghatak, A.T. & Miller, R.L. (2001) Anaphylaxis in the United States: an investigation into its epidemiology. Archives of Internal Medicine 161, 15-21.
114. Plaud, B., Donati, F. & Debaene, B. (2002) Anaphylaxis during anaesthesia. British Journal of Anaesthesia 88, 604-606.
115. Pleuvry, B.J. (2005) Pharmacokinetics: familial variation in drug response. Anaesthesia and Intensive Care Medicine 6, 243-244.
116. Stewart, A.G. & Ewan, P.W. (1996) The incidence, aetiology and management of anaphylaxis presenting to an accident and emergency department. Quarterly Journal of Medicine 89, 859-864.
117. Briggs, L.P., Clarke, R.S.J., Dundee, J.W., et al. (1981) Use of diisopropylphenol as main agent for short procedures. British Journal of Anaesthesia 53, 1197-1202.
118. Doenicke, A. (1974) Etomidate: a new intravenous hypnotic. Acta Anaesthesiologica Belgica 25, 307-315.
119. Doenicke, A.W., Roizen, M.F., Hoernecke, R., et al. (1999) Solvent for etomidate may cause pain and adverse effects. British Journal of Anaesthesia 83, 464-466.
120. Domino, E.F., Chodoff, P. & Corssen, G. (1965) Pharmacologic effects of CI 581, a new dissociative anesthetic in man. Clinical Pharmacology and Therapeutics 6, 279-290.
121. Dundee, J.W. & Wyant, G.M. (1988) Intravenous Anaesthesia. Edinburgh: Churchill Livingstone.
122. Firestone, L.L., Quinlan, J.J. & Homanics, G.E. (1995) The role of gamma-amino butyric acid Type-A receptor subtypes in the pharmacology of general anaesthesia. Current Opinion in Anesthesiology 8, 311-314.
123. Fryer, J.M. (2001) Intravenous induction agents. Anaesthesia and Intensive Care Medicine 2, 277-281.
124. Hocking, G. & Cousins, M.J. (2003) Ketamine in chronic pain management: an evidence-based review. Anesthesia and Analgesia 97, 1730-1739.
125. Laroche, D., Vergnaud, M.C., Sillard, B., et al. (1991) Biochemical markers of anaphylactoid reactions to drugs: comparison of plasma histamine and tryptase. Anesthesiology 75, 945-949.
126. Liljeroth, E. & Akeson, J. (2005) Less local pain on intravenous infusion of a new propofol emulsion. Acta Anaesthesiologica Scandinavica 49, 248-251.
127. Lingren, L. (1994) Anaesthetic activity and side effects of propofol. Current Opinion in Anaesthesiology 7, 321-325.
128. Lundy, J.S. (1935) Intravenous anesthesia: preliminary report of the use of two new thiobarbiturates. Proceedings of Staff Meetings of the Mayo Clinic 10, 534-543.
129. Mirakhur, R.K. &Morgan, M. (1998) Intravenous anaesthesia: a step forward. Anaesthesia 53(Suppl 1), 1-3.
130. Nau, C. & Strichartz, G.R. (2002) Drug chirality in anaesthesia. Anesthesiology 97, 497-502.
131. Parke, T.J., Stevens, J.E., Rice, A.S.C., et al. (1992) Metabolic acidosis and fatalmyocardial failure after propofol infusion in children: five case reports. British Medical Journal 305, 613-615.
132. Sneyd, J.R. (2004) Recent advances in intravenous anaesthesia. British Journal of Anaesthesia 93, 725-736.
133. Tanelian, D.L., Kosek, P.,Mody, I. &MacIver, M.B. (1993) The role ofGABAA receptor/chloride channel complex in anaesthesia. Anesthesiology 78, 757-776.
134. Theilen, H.J., Adam, S., Albrecht, M.D. & Ragaller, M. (2002) Propofol in a medium and long-chain triglyceride emulsion: pharmacological characteristics and potential beneficial effects. Anesthesia and Analgesia 95, 923-929.
135. Tomlin, S.L., Jenkins, A., Lieb, W.R., et al. (1998) Stereoselective effects of etomidate optical isomers on gammaaminobutyric acid Type A receptors and animals. Anesthesiology 88, 708-717.
136. Trotter, C. & Serpell, M.G. (1992) Neurological sequelae in children after prolonged propofol infusion. Anaesthesia 47, 340-342.
137. Veroli, P., O'Reilly, B., Bertrand, F., et al. (1992) Extrahepatic metabolism of propofol in man during the anhepatic phase of orthoptic liver transplantation. British Journal of Anaesthesia 68, 183-186.
138. Vuyk, J., Schnider,T.P.&Engbers,F. (2000) Populationpharmacokinetics of propofol for target-controlled infusion (TCI) in the elderly. Anesthesiology 93, 1557-1558.
139. White, P.F.,Ham, J.,Way,W.L.&Trevor, A.J. (1980) Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52, 231-239.
140. Yamakura, T., Bertaccini, E., Trudell, J.R. &Harris, R.A. (2001) Anesthetics and ion channels: molecular models and sites of action. Annual Review of Pharmacology and Toxicology 41, 23-51.
141. Antognini, J.F. & Carstens, E. (2002) In vivo characterisation of clinical anaesthesia and its components. British Journal of Anaesthesia 89, 156-166.
142. Belelli, D., Pistis, M., Peters, J.A. & Lambert, J.J. (1999) General anaesthetic action at transmitter-gated inhibitory amino acid receptors. Trends in Pharmacological Sciences 20, 496-502.
143. Daniels, S. & Smith, E.B. (1993) Effects of general anaesthetics on ligand-gated ion channels. British Journal of Anaesthesia 71, 59-64.
144. Eger, E.I., II (ed.) (1974) Anesthetic Uptake and Action. Baltimore: Williams andWilkins.
145. Eger, E.I., II. (1994) Newinhaled anesthetics. Anesthesiology 80, 906-922.
146. Eger, E.I., II, Saidman, L.J. & Bandstater, B. (1965) Minimum alveolar concentration: a standard of anesthetic potency. Anesthesiology 26, 756-763.
147. Franks, N.P. & Lieb,W.R. (1994) Molecular and cellular mechanisms of general anaesthesia. Nature 367, 607-614.
148. Harper, N. (2001) Inhalational anaesthetics. Anaesthesia and Intensive Care Medicine 2, 241-245.
149. Hatch, D.J. (1999) New inhalation agents in paediatric anaesthesia. British Journal of Anaesthesia 83, 42-49.
150. Hess,W., Kannmacher, J. & Kruse, J. (2004) Contamination of anaesthetic gases with nitric oxide and its influence on oxygenation: study in patients undergoing open heart surgery. British Journal of Anaesthesia 93, 629-633.
151. Jones, R.M., Cashman, J.N., Eger, E.I., II, Damask, M.C. & Johnson, B.H. (1990) Kinetics and potency of desflurane (I-653) in volunteers. Anesthesia and Analgesia 70, 3-7.
152. Kharasch, E.D., Hankins, D., Mautz, D. & Thummel, K.E. (1996) Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 347, 1367-1371.
153. Mapleson, W.W. (1996) Effect of age on MAC in humans: a meta-analysis. British Journal of Anaesthesia 76, 179-185.
154. Murat, I., Dubois, M.C. & Piat, V. (1995) Sevoflurane. Annales Francaises d'Anesthesie et de Reanimation 14, 489-501.
155. Nunn, J.F. (1987) Clinical aspects of the interaction between nitrous oxide and vitamin B12. British Journal of Anaesthesia 59, 3-13.
156. Nunn, J.F., Chanarin, I., Tanner, A.G. & Owen, E.R.T.C. (1986) Megaloblastic bone marrow changes after repeated nitrous oxide anaesthesia. British Journal of Anaesthesia 58, 1469-1470.
157. Priebe, H.J. (1989) Isoflurane and coronary hemodynamics. Anesthesiology 71, 960-976.
158. Smith, I., Nathanson, M. & White, P.F. (1996) Sevoflurane-a long-awaited volatile anaesthetic. British Journal of Anaesthesia 76, 435-445.
159. Stoetling, R.K.&Eger, E.I., II. (1969) An additional explanation for the second gas effect: a concentrating effect. Anesthesiology 30, 273-277.
160. Terrell, R.C. (1984) Physical and chemical properties of anaesthetic agents. British Journal of Anaesthesia 56, 3S-7S.
161. Urban, B.W. (2002) Current assessment of targets and theories of anaesthesia. British Journal of Anaesthesia 89, 167-183.
162. Bardsley, H., Gristwood, R., Baker, H., Watson, N. & Nimmo, W. (1998) A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. British Journal of Clinical Pharmacology 46, 245-249.
163. Bay-Nielsen, M., Klarskov, B., Bech, K., Andersen, J. & Kehlet, H. (1999) Levobupivacaine vs bupivacaine as infiltration anaesthesia in inguinal herniorrhaphy. British Journal of Anaesthesia 82, 280-282.
164. Benhamou, D., Hamza, J., Eledjam, J.J., et al. (1997) Continual extradural infusion of ropivacaine 2 mg mL-1 for pain relief during labour. British Journal of Anaesthesia 78, 748-750.
165. Brockway, M.S., Bannister, J., McClure, J.H., McKeown, D. & Wildsmith, J.A.W. (1991) Comparison of extradural ropivacaine and bupivacaine. British Journal of Anaesthesia 66, 31-37.
166. Catterall, W.A. (1993) Structure and function of voltagegated ion channels. Trends in Neurosciences 16, 500-506.
167. Covino, B.G. (1986) Pharmacology of local anaesthetic agents. British Journal of Anaesthesia 58, 701-716.
168. Cox, C.R., Faccenda, K.A., Gilhooly, C., Bannister, J., Scott, N.B. & Morrison, L.M.M. (1998) Extradural S(-) bupivacaine: comparison with racemic RS-bupivacaine. British Journal of Anaesthesia 80, 289-293.
169. Denny, N.M.&Selander,D.E. (1998) Continuous spinal anaesthesia. British Journal of Anaesthesia 81, 590-597.
170. Duncan, L. &Wildsmith, J.A.W. (1995) Liposomal local anaesthetics. British Journal of Anaesthesia 75, 260-261.
171. Foster, R.H. &Markham, A. (2000) Levobupivacaine: a review of its pharmacology and use as a local anaesthetic. Drugs 59, 551-579.
172. Kopacz, D.J., Allen, H.W. & Thompson, G.E. (2000) A comparison of epidural levobupivacaine 0.75% with racemic bupivacaine for lower abdominal surgery. Anesthesia and Analgesia 90, 642-648.
173. Lyons, G., Columb, M., Wilson, R.C. & Johnson, R.V. (1995) Epidural pain relief in labour: potencies of levobupivacaine and racemic bupivacaine. British Journal of Anaesthesia 81, 899-901.
174. McClure, J.H. (1996) Ropivacaine. British Journal ofAnaesthesia 76, 300-307.
175. McCrae, A.F., Jozwiak, H. &McClure, J.H. (1995) Comparison of ropivacaine and bupivacaine in extradural analgesia for the relief of pain in labour. British Journal of Anaesthesia 74, 261-265.
176. Morrison, L.M.M., Emanuelsson, B.M., McClure, J.H., et al. (1994) Efficacy and kinetics of extradural ropivacaine: comparison with bupivacaine. British Journal of Anaesthesia 72, 164-169.
177. Narahashi,T.,Yamada,M.&Frazier,D.T. (1969) Cationic forms of local anesthetics block action potentials from inside the nerve membrane. Nature 223, 748-749.
178. Reynolds, F. (1987) Adverse effects of local anaesthetics. British Journal of Anaesthesia 59, 78-95.
179. Santos, A.C.,Karpel, B.&Noble, G. (1990) The placental transfer and fetal effects of levobupivacaine, racemic bupivacaine and ropivacaine. Anesthesiology 90, 1698-1703.
180. Scott, D.B. (1986) Toxic effects of local anaesthetic agents on the central nervous system. British Journal of Anaesthesia 58, 732-735.
181. Tucker, G.T. (1986) Pharmacokinetics of local anaesthetics. British Journal of Anaesthesia 58, 717-731.
182. Wahedi,W., Nolte, H. & Kline, P. (1996) Ropivacaine in spinal anaesthesia. Anaesthetist 45, 737-744.
183. Wann, K.T. (1993) Neuronal sodium and potassium channels: structure and function. British Journal of Anaesthesia 71, 2-14.
184. Whiteside, J.B., Burke, D. & Wildsmith, J.A.W. (2001) Spinal anaesthesia with ropivacaine 5 mg mL-1 in glucose 10 mg mL-1 or 50 mg mL-1. British Journal of Anaesthesia 86, 241-244.
185. Whiteside, J.B. & Wildsmith, J.A.W. (2001) Developments in local anaesthetic drugs. British Journal of Anaesthesia 87, 27-35.
186. Berg, H., Roed, J. & Viby-Mogensen, J., et al. (1997) Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiologica Scandinavica 41, 1095-1103.
187. Bevan,D.R. (1994) Succinylcholine. Canadian Journal ofAnaesthesia 41, 465-468.
188. Caldwell, J. (1995) New muscle relaxants. Current Opinion in Anaesthesiology 8, 356-361.
189. Calvey, T.N. (1984) Assessment of neuromuscular blockade by electromyography: a review. Journal of the Royal Society of Medicine 77, 56-59.
190. Changeux, J.-P., Giraudat, J.&Dennis, M. (1987) The nicotinic acetylcholine receptor: molecular architecture of a ligandregulated ion channel. Trends in Pharmacological Sciences 8, 459-465.
191. Fleming, N.W. & Lewis, B.K. (1994) Cholinesterase inhibitors do not prolong neuromuscular block produced by mivacurium. British Journal of Anaesthesia 73, 241-243.
192. Kopman, A.F., Klewicka, M.M., Kopman,D.J. &Neuman, G.G. (1999) Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration. Anesthesiology 90, 425-431.
193. Lee, C. (2001) Structure, conformation, and action of neuromuscular blocking drugs. British Journal of Anaesthesia 87, 755-769.
194. Martyn, J.A. (1999) Succinylcholine hyperkalemia after burns. Anesthesiology 91, 321-322.
195. O'Sullivan, E.P., Williams, N.E. & Calvey, T.N. (1988) Differential effects of neuromuscular blocking agents on suxamethonium-induced fasciculations and myalgia. British Journal of Anaesthesia 60, 367-371.
196. Paton, W.D.M. & Waud, D.R. (1967) The margin of safety of neuromuscular transmission. Journal of Physiology 191, 59-90.
197. Pollard, B.J. (2005) Neuromuscular blocking agents and reversal agents. Anaesthesia and Intensive Care Medicine 6, 189-192.
198. Rosenberg, H.&Gronert, G.A. (1992) Intractable cardiac arrest in children given succinylcholine. Anesthesiology 77, 1054.
199. Roy, J.J. & Varin, F. (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship. British Journal of Anaesthesia 93, 241-248.
200. Sardesai, A.M. & Griffiths, R. (2005) Monitoring techniques: neuromuscular blockade. Anaesthesia and Intensive Care Medicine 6, 198-200.
201. Stenlake, J.B., Waigh, R.D., Urwin, J., Dewar, G.H. & Coker, G.G. (1983) Atracurium: conception and inception. British Journal of Anaesthesia 55(Suppl 1), S3-S10.
202. Sudhof, T.C. & Jahn, R. (1991) Proteins of synaptic vesicles involved in exocytosis and membrane recycling. Neurone 6, 665-667.
203. Tolmie, J.D., Joyce, T.H. & Mitchell, G.D. (1967) Succinylcholine danger in the burned patient. Anesthesiology 28, 467-470.
204. Ward, J.M. & Martyn, J.A. (1993) Burn injury-induced nicotinic acetylcholine receptor changes on muscle membrane. Muscle Nerve 16, 348-354.
205. Wareham, A.C. (2005) Neuromuscular function and transmission. Anaesthesia and Intensive Care Medicine 6, 203-205.
206. Wareham, A.C. (2005) Muscle. Anaesthesia and Intensive Care Medicine 6, 209-212.
207. Whittaker, V.P. (1986) The storage and release of acetylcholine. Trends in Pharmacological Sciences 7, 312-315.
208. Wong, S.F.&Chung, F. (2000) Succinylcholine associated postoperative myalgia. Anaesthesia 55, 144-152.
209. Zhang, M.Q. (2003) Drug-specific cyclodextrins: the future of rapid neuromuscular reversal? Drugs Future 28, 347-354.
210. Corbett, A.D., Henderson, G., McKnight, A.T. & Paterson, S.J. (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail. British Journal of Pharmacology 147, S153-S162.
211. Darland, T.&Grandy,D.K. (1998) The orphaninFQsystem: an emerging target for the management of pain? British Journal of Anaesthesia 81, 29-37.
212. Dray, A., Urban, L. & Dickenson, A. (1994) Pharmacology of chronic pain. Trends in Pharmacological Sciences 15, 190-197.
213. Duthie, D.J.R. (1998) Remifentanil and tramadol. British Journal of Anaesthesia 81, 51-57.
214. Finck, A.D. (1989) Opiate receptors and endogenous opioid peptides. Current Opinion in Anaesthesiology 2, 428-433.
215. Glass, P.S.A., Hardman, D. & Kamiyama, Y., et al. (1993) Preliminary pharmacokinetics and pharmacodynamics of an ultra-short acting opioid remifentanil (G187084B). Anesthesia and Analgesia 77, 1031-1040.
216. Henderson, G. & McKnight, A.T. (1997) The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ. Trends in Pharmacological Sciences 18, 293-300.
217. Hoskin, P.J. & Hanks, G.W. (1991) Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 41, 326-344.
218. Keeble, J.E. & Moore, P.K. (2002) Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxidedonating drugs. British Journal of Pharmacology 137, 295-310.
219. Martin,W.R., Eades, C.G. & Thompson, J.A., et al. (1976) The effects ofmorphine-and nalorphine-like drugs in the nondependent chronic spinal dog. Journal of Pharmacology and Experimental Therapeutics 97, 517-532.
220. Melzack,R.&Wall, P.D. (1965) Pain mechanisms: a new theory. Science 150, 971-979.
221. Mitchell, R.W.D. & Smith, G. (1989) The control of acute postoperative pain. British Journal of Anaesthesia 63, 147-158.
222. Morgan, M. (1989) Use of intrathecal and extradural opioids. British Journal of Anaesthesia 63, 165-188.
223. Pasternak,G.W. (1993) Pharmacologicalmechanisms of opioid receptors. Clinical Neuropharmacology 16, 1-18.
224. Pasternak, G.W. (2005) Molecular biology of opioid analgesia. Journal of Pain Symptom Management 29, S2-S9.
225. Pert, C.B. & Snyder, S.H. (1973) Opiate receptor; demonstration in nervous tissue. Science 179, 1011-1014.
226. Pleuvry, B.J. (1993) Opioid receptors and their relevance to anaesthesia. British Journal of Anaesthesia 71, 119-126.
227. Power, I. (2005) Recent advances in postoperative pain therapy. British Journal of Anaesthesia 95, 43-51.
228. Rathmell, J.P., Lair, T.R. & Naumann, B. (2006) The role of intrathecal drugs in the treatment of acute pain. Anesthesia and Analgesia 101(Suppl 5), S30-S43.
229. Richmond, C.E., Bromley, L.M. &Woolf, C.J. (1993) Preoperative morphine pre-empts postoperative pain. Lancet 342, 73-75.
230. Sear, J.W. (1998) Recent advances and developments in the clinical use of i.v. opioids during the preoperative period. British Journal of Anaesthesia 81, 38-50.
231. Shetty, P.S. & Picard, J. (2006) Adjuvant agents in regional anaesthesia. Anaesthesia and Intensive CareMedicine 7, 407-410.
232. Vane, J.R.&Botting, R.M. (1995) Newinsights into the mode of action of anti-inflammatory drugs. Inflammation Research 44, 1-10.
233. Waldhoer, M., Bartlett, S.E. & Whistler, J.L. (2004) Opioid receptors. Annual Review of Biochemistry 73, 953-990.
234. Wall, P.D. &Melzack, R. (eds) (1999) Textbook of Pain, 4th edn. Edinburgh: Churchill Livingstone.
235. Watkins,P.B.,Kaplowitz, N.&Slattery, J.T., et al. (2006)Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. Journal of the American Medical Association 296, 87-93.
236. Bormann, J. (2000) The 'ABC' of GABA receptors. Trends in Pharmacological Sciences 21, 16-19.
237. Diemunsch, P., Schoeffler, P., Bryssine, B., et al. (1999) Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. British Journal of Anaesthesia 82, 274-276.
238. Fisher, D.M. (1997) The 'big little problem' of postoperative nausea and vomiting: do we know the answer yet? Anesthesiology 87, 1271-1273.
239. Gesztesi, Z.S., Song, D. & White, P.F. (1998) Comparison of a new NK1 receptor antagonist (CP122,721) to ondansetron in the prevention of postoperative nausea and vomiting. Anesthesia and Analgesia 86(Suppl 2), S32.
240. Hayashi, Y. & Maze, M. (1993) Alpha2 adrenoceptor agonists and anaesthesia. British Journal of Anaesthesia 71, 108-118.
241. Heffernan, A.M.&Rowbotham,D.J. (2000) Postoperative nausea and vomiting-time for balanced antiemesis? British Journal of Anaesthesia 85, 675-677.
242. Henzi, I., Walder, B. & Tramer, M.R. (1999) Metoclopramide in the prevention of postoperative nusea and vomiting: a quantitative systematic review of randomized, placebocontrolled studies. British Journal of Anaesthesia 83, 761-771.
243. Johnston, G.A.R. (1996) GABAA receptor pharmacology. Pharmacology and Therapeutics 69, 173-198.
244. Lee, C.R., Plosker, G.L. & McTavish, D. (1993) Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 46, 925-943.
245. Markham, A. & Sorkin, E.M. (1993) Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45, 931-952.
246. McDonald, R.L. & Olsen, R.W. (1994) GABAA receptor channels. Annual Review of Neuroscience 17, 569-602.
247. Mitchelson, F. (1992) Pharmacological agents affecting emesis: a review (Part I). Drugs 43, 295-315.
248. Mitchelson, F. (1992) Pharmacological agents affecting emesis: a review (Part II). Drugs 43, 443-463.
249. Pleuvry, B. (2001) Anxiolytics and hypnotics. Anaesthesia and Intensive Care Medicine 2, 233-236.
250. Pleuvry, B. (2001) Premedication. Anaesthesia and Intensive Care Medicine 2, 245-249.
251. Plosker, G.L. & Goa, K.L. (1991) Granisetron: a review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 42, 805-824.
252. Reynolds, J.M. & Blogg, C.E. (1995) Prevention and treatment of postoperative nausea and vomiting. Prescribers Journal 35, 111-116.
253. Rose, J.B.&Watcha,M.F. (1999) Postoperative nauseaandvomiting in paediatric patients. British Journal ofAnaesthesia 83, 104-117.
254. Rosen, M. & Camu, F. (1994) Postoperative nausea and vomiting. Anesthesia 49, 1-11.
255. Rowbotham,D.J. (1992)Current management of postoperative nausea and vomiting. British Journal ofAnaesthesia 69, 46S-59S.
256. Rust, M. (1995) Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting. Anaesthetist 44, 288-290.
257. Sieghart, W. (1995) Structure and pharmacology of γ-aminobutyric acidA receptor subtypes. Pharmacological Reviews 47, 182-234.
258. Sigel, E. & Buhr, A. (1997) The benzodiazepine binding site of GABAA receptors. Trends in Pharmacological Sciences 18, 425-429.
259. Sinclair, D.R., Chung, F. &Mezei, G. (1999) Can postoperative nausea and vomiting be predicted? Anesthesiology 91, 109-118.
260. Tanelian, D.L., Kosek, P.,Mody, I. &MacIver, M.B. (1993) The role of the GABAA receptor/chloride channel complex in anesthesia. Anesthesiology 78, 757-776.
261. Tramer, M.L. (2001) A rational approach to the control of PONV: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiologica Scandinavica 45, 4-14.
262. Tramer, M.L. (2001) A rational approach to the control of PONV: evidence from systematic reviews. Part II. Recommendations for prevention and treatment, and research agenda. Acta Anaesthesiologica Scandinavica 45, 14-20.
263. Watcha, M.F. & White, P.F. (1992) Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 77, 162-184.
264. Watcha, M.F. & White, P.F. (1999) Postoperative nausea and vomiting. Prophylaxis versus treatment. Anesthesia and Analgesia 89, 1337-1339.
265. White, P.F. (1995) Management of postoperative pain and emesis. Canadian Journal of Anaesthesia 42, 1053-1055.
266. Ahlquist, R.R. (1948)Astudy of the adrenergic receptors.American Journal of Physiology 153, 586-600.
267. Barnett, D.B. (1948) Myocardial β-adrenoceptor function and regulation in heart failure: implications for therapy. British Journal of Clinical Pharmacology 27, 527-538.
268. Boldt, J., Knothe, C., Zickmann, B., et al. (1992) The role of enoximone in cardiac surgery. British Journal of Anaesthesia 69, 45-50.
269. Craven, J. (2005) The autonomic nervous system, sympathetic chain and stellate ganglion. Anaesthesia and Intensive Care Medicine 6, 37-38.
270. Goldberg, L.I. (1974) Dopamine-clinical uses of an endogenous catecholamine. New England Journal ofMedicine 291, 707-710.
271. Goyal, R.K. (1989) Muscarinic receptor subtypes: physiology and clinical implications. New England Journal of Medicine 321, 1022-1029.
272. Guinmaraes, S.&Moura,D. (2001) Vascular adrenoceptors: an update. Pharmacological Reviews 53, 319-356.
273. Handy, J.M. & Cordingley, J. (2003) Postoperative cardiac intensive care. Anaesthesia and Intensive CareMedicine 4, 258-261.
274. Hayashi, Y. & Maze, M. (1993) Alpha2 adrenoceptor agonists and anaesthesia. British Journal of Anaesthesia 71, 108-118.
275. Hieble, I.P., Bondinell, W.E. & Ruffolo, R.R. (1995) α-and β-adrenoceptors; from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. Journal of Medicinal Chemistry 38, 3415-3444.
276. Hulme, E.C.,Birdsall, N.J.M.&Buckley, N.J. (1990)Muscarinic receptor subtypes.Annual Reviewof Pharmacology and Toxicology 30, 633-673.
277. Insel, P.A. (1996) Adrenergic receptors-evolving concepts and clinical implications. New England Journal ofMedicine 334, 580-585.
278. Kilbinger, H. (1984) Presynaptic muscarinic receptors modulating acetylcholine release. Trends in Pharmacological Sciences 5, 103-105.
279. Langer, S.Z. &Hicks, P.E. (1984) Physiology of the sympathetic nerve ending. British Journal of Anaesthesia 56, 689-700.
280. Liu, Y. & Edwards, R.H. (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annual Review of Neurosciences 20, 125-156.
281. Pleuvry, B.J. (2005) Drugs affecting the autonomic nervous system. Anaesthesia and Intensive Care Medicine 6, 34-36.
282. Ruffolo, R.R. (1987) The pharmacology of dobutamine. American Journal of Medical Sciences 294, 244-248.
283. Ruffolo, R.R., Bondinell, W. & Hieble, J.P. (1995) α-and β-adrenoceptors; from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Journal of Medicinal Chemistry 38, 3681-3716.
284. Saravanan, S., Kocarev, M.,Wilson, R.C.,Watkins, E., Columb, M.O. & Lyons, G. (2006) Equivalent dose of ephedrine and phenylephrine in the prevention of post-spinal hypotension in Caesarean section. British Journal of Anaesthesia 96, 95-99.
285. Small, R. (2001) Pharmacological modulation of myocardial function, vascular resistance and blood pressure: drugs used during cardiopulmonary resuscitation. Anaesthesia and Intensive Care Medicine 2, 34-39.
286. Starke, K., Gothert, M. & Kilbinger, H. (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiological Reviews 69, 864-989.
287. Stephan, H., Sonntag, H., Henning, H. & Yoshimine, K. (1990) Cardiovascular and renal haemodynamic effects of dopexamine: comparison with dopamine. British Journal of Anaesthesia 65, 380-387.
288. Summers, R.J. & McMartin, L.R. (1993) Adrenoceptors and their second messenger systems. Journal of Neurochemistry 60, 10-23.
289. Zaugg, M., Schaub, M.C., Pasch, T. & Spahn,D.R. (2002) Modulation of β-adrenergic receptor subtype activities in perioperativemedicine: mechanisms and sites of action. British Journal of Anaesthesia 88, 101-123.
290. Aitken, D. (1977) Cyanide toxicity following nitroprusside induced hypotension. Canadian Anaesthetists Society Journal 24, 651-660.
291. Antonaccio, M.J. (1982) Angiotensin-converting-enzyme (ACE) inhibitors. Annual Review of Pharmacology and Toxicology 27, 57-87.
292. Bearner, J.E.R. &Warwick, J. (2001) Critical incidents: the cardiovascular system. Anaesthesia and Intensive CareMedicine 2, 412-417.
293. Burnier, M. & Brunner, H.R. (2000) Angiotensin II receptor antagonists. Lancet 355, 637-645.
294. Elsharnouby, N.M. & Elsharnouby, M.M. (2006) Magnesium sulphate as a technique of hypotensive anaesthesia. British Journal of Anaesthesia 96, 727-731.
295. Goldman, L. & Caldera, D.L. (1979) Risks of general anaesthesia and elective operation in the hypertensive patient. Anaesthesiology 50, 285-292.
296. Howell, S.J., Sear, J.W. & Foëx, P. (2001) Peri-operative β-blockade: a useful treatment that should be greeted with cautious enthusiasm. British Journal of Anaesthesia 86, 161-164.
297. Howell, S.J., Sear, J.W. & Foëx, P. (2004) Hypertension, hypertensive heart disease and perioperative cardiac risk. British Journal of Anaesthesia 92, 570-583.
298. Jacobi, K.E., Bohmo, B.E., Rickauer, A.J., Jacobi,C.&Hemmerling, T.M. (2000) Moderate controlled hypotension with sodium nitroprusside does not improve surgical conditions or decrease blood loss in endoscopic sinus surgery. Journal of Clinical Anesthesia 12, 202-207.
299. Johnston, C.I. (1995) Angiotensin receptor antagonists: focus on losartan. Lancet 346, 1403-1407.
300. Jones, K.G. & Powell, J.T. (2000) Slowing the heart saves lives: advantages of perioperative of perioperative β-blockade. British Journal of Surgery 87, 689-690.
301. Kaplan, N.M. &Opie, L.H. (2006) Controversies in Cardiology 2. Controversies in hypertension. Lancet 367, 168-176.
302. Leigh, J.M. (1975) The history of controlled hypotension. British Journal of Anaesthesia 47, 745-749.
303. Lenders, J.W.M., Eisenhofer, G., Mannelli, M. & Pacak, K. (2005) Phaechromocytoma. Lancet 366, 665-675.
304. Lindholm, L.H., Carlberg, B. & Samuelsson, O. (2005) Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366, 1545-1553.
305. MacIndoe, A.K. (2002) Recognition and management of phaeochromocytoma. Anaesthesia and Intensive Care Medicine 3, 319-324.
306. Moss, E. (1994) Cerebral blood flow during induced hypotension. British Journal of Anaesthesia 74, 635-637.
307. Nicolson, D.J., Dickinson, H.O., Campbell, F. & Mason, J.M. (2004) Lifestyle interventions or drugs for patients with essential hypertension: a systematic review. Journal of Hypertension 22, 2043-2048.
308. Prys-Roberts, C., Meloche, R. & Foëx, P. (1971) Studies of anaesthesia in relation to hypertension. I. Cardiovascular responses of treated and untreated patients. British Journal of Anaesthesia 43, 122-137.
309. Sambrook, A. & Small, R. (2003) Antiarrhythmic drugs: antihypertensive drugs in pregnancy. Anaesthesia and Intensive Care Medicine 4, 266-272.
310. Small, R. (2001) Pharmacological modulation of myocardial function, vascular resistance and blood pressure. Anaesthesia and Intensive Care Medicine 2, 34-39.
311. Spahn, D.R. & Priebe, H.-J. (2004) Preoperative hypertension: remain wary? 'Yes'-cancel surgery? 'No'. British Journal of Anaesthesia 92, 461-464.
312. Aggarwal, A. & Wartlier, D.C. (1994) Adenosine: present uses, future indications. Current Opinion in Anaesthesiology 7, 109-123.
313. Barnett, D.B. (1988) Myocardial ischaemia: progress in drug therapy. British Journal of Anaesthesia 61, 11-23.
314. Booker, P.D., Whyte, S.D. & Ladusans, E.J. (2003) Long QT syndrome and anaesthesia. British Journal of Anaesthesia 90, 349-366.
315. Ertel, S.I. & Ertel, E.A. (1999) Low-voltage-activated T-type Ca2+channels. Trends in Pharmacological Sciences 18, 37-42.
316. Fawcett, W.J., Haxby, E.J. & Male, D.A. (1999) Magnesium: physiology and pharmacology. British Journal ofAnaesthesia 83, 302-309.
317. Godfraind, T.&Govani, S. (1995) Recent advances in the pharmacology of Ca2+ and K+ channels. Trends in Pharmacological Sciences 16, 1-4.
318. Hammil, S. & Hubmayr, R. (2000) The rapidly changing management of cardiac arrhythmias. American Journal of Respiratory and Critical Care Medicine 161, 1070-1073.
319. Ijzerman, A.P. & Soudijn,W. (1989) The antiarrhythmic properties of α-adrenoceptor antagonists. Trends in Pharmacological Sciences 10, 31-36.
320. Kaplinsky, E. (1992) Management of angina pectoris. Modern concepts. Drugs 43(Suppl 1), 9-14.
321. Kirkman, E. (2006) Initiation and regulation of the heartbeat. Anaesthesia and Intensive Care Medicine 7, 255-258.
322. Kirkman, E. (2006) Myocardial action potential. Anaesthesia and Intensive Care Medicine 7, 259-263.
323. Kirkman, E. (2006) The electrocardiogram. Anaesthesia and Intensive Care Medicine 7, 264-266.
324. Nestico, P.F.,Morganroth, J. & Horowitz, L.N. (1988) New antiarrhythmic drugs. Drugs 35, 286-319.
325. Reiz, S. (1988) Myocardial ischaemia associated with general anaesthesia. British Journal of Anaesthesia 61, 68-84.
326. Richards, K.J.C. & Cohen, A.T. (2001) Cardiac arrhythmias in the critically ill. Anaesthesia and Intensive Care Medicine 2, 384-389.
327. Roden, D.M. (1994) Risks and benefits of antiarrhythmic drug therapy. New England Journal of Medicine 331, 785-791.
328. Rutherford, J.D. (1993) Pharmacologic management of angina and acute myocardial infarction. American Journal of Cardiology 72, 16C-20C.
329. Sambrook, A. & Small, R. (2003) Antiarrhythmic drugs; antihypertensive drugs in pregnancy. Anaesthesia and Intensive Care Medicine 4, 266-272.
330. Silvestry, F.E.&Kimmel, S.E. (1996) Calcium-channel blockers in ischaemic heart disease. Current Opinion in Cardiology 11, 434-439.
331. Thadani,U. (1992)Role of nitrates inangina pectoris.American Journal of Cardiology 70, 43B-53B.
332. Van Zweiten, P.A. (1996) Clinical pharmacology of calcium antagonists as antihypertensive and anti-anginal drugs. Journal of Hypertension 14(Suppl), S3-S9.
333. VaughanWilliams, E.M. (1992) Classifying antiarrhythmic actions: by facts or speculation. Journal of Clinical Pharmacology 32, 964-977.
334. Anderson, J.A.M. & Saenko, E.L. (2002) Heparin resistance. British Journal of Anaesthesia 88, 467-469.
335. Anderson, K.M., Califf, R.M., Stone, G.W., et al. (2001) Longterm mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology 37, 2059-2065.
336. Aster, R.H. (1995) Heparin-induced thrombocytopenia and thrombosis. New England Journal of Medicine 332, 1374-1376.
337. Bullingham, A. & Strunin, L. (1995) Prevention of postoperative thromboembolism. British Journal of Anaesthesia 75, 622-630.
338. Chong, B.H. (1995) Heparin-induced thrombocytopenia. British Journal of Haematology 89, 421-439.
339. Collins, R., Peto, R., Baigent, C. & Sleight, P. (1997) Aspirin, heparin and thrombolytic therapy in suspected acute myocardial infarction. New England Journal of Medicine 336, 847-860.
340. Davie, E.W., Fujikawa, K. & Kisiel, W. (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363-10370.
341. Diener, H., Cunha, L., Forbes, C., et al. (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Science 143, 1-14.
342. Furie, B. & Furie, B.C. (1992) Molecular and cellular biology of blood coagulation. New England Journal ofMedicine 326, 800-806.
343. Green, C. (2003) DIC and other coagulopathies in the ICU. Anaesthesia and Intensive Care Medicine 4, 147-149.
344. Hirsh, J. (1991)Heparin.New England Journal ofMedicine 324, 1565-1574.
345. Hirsh, J. (1991) Oral anticoagulant drugs. New England Journal of Medicine 324, 1865-1873.
346. Hirsh, J.&Levine, M.N. (1992) Low molecular weight heparin. Blood 79, 1-17.
347. Kaplan, K. & Francis, C. (1999) Heparin induced thrombocytopenia. Blood Review 13, 1-7.
348. Kövesi, T. & Royston, D. (2002) Is there a bleeding problem with platelet-active drugs? British Journal of Anaesthesia 88, 159-163.
349. Mannuccio,M. (1998)Hemostatic drugs.New England Journal of Medicine 333, 245-253.
350. Martlew, V.J. (2000) Peri-operative management of patients with coagulation disorders. British Journal of Anaesthesia 85, 446-455.
351. Montalescot, G., Barragan, P., Wittenberg, O., et al. (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acutemyocardial infarction. New England Journal of Medicine 344, 1895-1903.
352. Nichols, A.J., Ruffolo, R.R, Huffman, W.F., et al. (1992) Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends in Pharmacological Sciences 13, 413-417.
353. Patrono, C. (1994)Aspirin as an antiplatelet drug.NewEngland Journal of Medicine 330, 1287-1294.
354. Salzman, E.W. (1992) Low-molecular-weight heparin and other new antithrombotic drugs. New England Journal of Medicine 326, 1017-1019.
355. Schweizer, A., Höhn, L., Morel, D.R., et al. (2000) Aprotinin does not impair renal haemodynamics and function after cardiac surgery. British Journal of Anaesthesia 84, 16-22.
356. Turpie, A.G., Gallus, A.S. & Hoek, J.A. (2001) A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. New England Journal of Medicine 344, 619-625.
357. Trivier, J.M., Caron, J., Mahieu, M., et al. (2001) Fatal aplastic anaemia associated with clopidogrel. Lancet 357, 446.
358. Ware, J.A. & Heisted, D.D. (1993) Platelet-endothelium interactions. New England Journal of Medicine 328, 628-635.
359. Weitz, J.I. & Hirsh, J. (2001) New anticoagulant drugs. Chest 119, 95S-107S.
360. Wong, B.I., McLean, R.F., Fremes, S.E., et al. (2000) Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Annals of Thoracic Surgery 69, 808-816.
361. Alberti, K.G.M.M. & Thomas, D.J.B. (1979) The management of diabetes during surgery. British Journal of Anaesthesia 51, 693-710.
362. Barnes, P.J. & Adcock, I. (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends in Pharmacological Sciences 14, 436-441.
363. Barnett, A.H. & Owens, D.R. (1997) Insulin analogues. Lancet 349, 47-51.
364. Best, L. (2002) Pharmacological control of blood sugar. Anaesthesia and Intensive Care Medicine 3, 346-348.
365. Bolli, G.B. & Owens, D.R. (2000) Insulin glargine. Lancet 356, 443-445.
366. Cheatham, B. & Kahn, C.R. (1995) Insulin action and the insulin signaling network. Endocrinological Reviews 16, 117-142.
367. Christiansen, C.L., Schurizek, B.A., Malling, B., et al. (1988) Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery-continuous intravenous infusion compared with subcutaneous administration. Anaesthesia 43, 533-537.
368. Chrousos, G.P. (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New England Journal of Medicine 332, 1351-1362.
369. Dornhorst, A. (2001) Insulinotropic meglitinide analogues. Lancet 358, 1709-1716.
370. Dunnet, J.M.,Holman, R.R.,Turner, R.C., et al. (1988) Diabetes mellitus and anaesthesia-a survey of the peri-operative management of the patient with diabetes mellitus. Anaesthesia 43, 538-542.
371. Flower, R.J. (1988) Lipocortin and the mechanism of action of the glucocorticoids. British Journal of Pharmacology 94, 987-1015.
372. Fonseca, V., Rosenstock, J., Patwardhan, R., et al. (2000) Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: a randomized controlled trial. Journal of the AmericanMedical Association 283, 1695-1702.
373. Funder, J.W. (1997) Glucocorticoid and mineralocorticoid receptors, biology and clinical relevance. Annual Review of Medicine 48, 231-240.
374. Gill, G.V. & Alberti, K.G.M.M. (1989) Surgery and diabetes. Hospital Update 5, 327-336.
375. Heald, A. (2002) Adrenocortical hormones. Anaesthesia and Intensive Care Medicine 3, 327-330.
376. Kahn, C.R. (1994) Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43, 1066-1084.
377. Marx, J. (1995) How the glucocorticoids suppress immunity. Science 270, 232-233.
378. McAnulty, G.R. (2000) Anaesthetic management of patients with diabetes mellitus. British Journal of Anaesthesia 85, 80-90.
379. Owens,D.R., Zinman, B.&Bolli, G.B. (2001) Insulin today and beyond. Lancet 358, 739-746.
380. Philipson, L.H. & Steiner, D.F. (1995) Pas de deux ormore: the sulfonylurea receptor and K+ channels. Science 268, 372-373.
381. Porter, A.L. & McCrirrick, A. (2002) Anaesthetic management of the diabetic patient. Anaesthesia and Intensive Care Medicine 3, 316-319.
382. Ramirez, V.D. (1996) How do steroids act? Lancet 347, 630-631.
383. Saltiel, A.R. & Pessin, J.E. (2002) Insulin signaling pathways in space and time. Trends in Cell Biology 12, 65-70.
384. Scherpereel, P.A. (2001) Perioperative care of the diabetic patient. European Journal of Anaesthesia 18, 227-294.
385. Tan, G. (2002) The pancreas. Anaesthesia and Intensive Care Medicine 3, 330-333.
386. White, M.F. & Kahn, C.R. (1994) The insulin signaling system. Journal of Biological Chemistry 269, 1-4.
387. Wilckens, T. (1995) Glucocorticoids and immune function, physiological relevance and pathogenic potential of hormonal dysfunction. Trends in Pharmacological Sciences 16, 193-197.